{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+Alfa-2a+and+Ribavirin&page=4", "query": { "intervention": "Peginterferon Alfa-2a and Ribavirin", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 150, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+Alfa-2a+and+Ribavirin&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peginterferon+Alfa-2a+and+Ribavirin&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:47:14.098Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01446250", "title": "Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Boceprevir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2011-12", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 2, "location_summary": "Beverly Hills, California • Baltimore, Maryland", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446250" }, { "nct_id": "NCT01290679", "title": "An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TMC435", "type": "DRUG" }, { "name": "Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 393, "start_date": "2011-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-06-13", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 11, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Crestview Hills", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01290679" }, { "nct_id": "NCT01500772", "title": "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2012-03", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2016-08-01", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500772" }, { "nct_id": "NCT01888900", "title": "New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Chronic Hepatitis C", "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "DUAL", "type": "DRUG" }, { "name": "QUAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2013-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888900" }, { "nct_id": "NCT01483742", "title": "A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2012-04", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2016-08-01", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01483742" }, { "nct_id": "NCT00495391", "title": "Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2007-07", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 10, "location_summary": "Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00495391" }, { "nct_id": "NCT00078403", "title": "Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C", "Liver Disease" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2004-07", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078403" }, { "nct_id": "NCT00084279", "title": "CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InterMune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2004-04", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2009-07-03", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084279" }, { "nct_id": "NCT00845676", "title": "Treatment of Acute Hepatitis C Virus in HIV Co-Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Pegylated interferon alfa-2a + Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2008-03", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2020-05-18", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00845676" }, { "nct_id": "NCT01598090", "title": "Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "BIOLOGICAL" }, { "name": "Peginterferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 881, "start_date": "2012-06-14", "completion_date": "2015-05-15", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-14T11:47:14.098Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598090" } ] }